Ironwood Financial’s VYNE Therapeutics VYNE Stock Holding History

Ironwood Financial’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	540
2021 Q3	$0	Hold	1	–	–	﹤0.01%	600
2021 Q2	$0	Hold	1	–	–	﹤0.01%	587
2021 Q1	$0	Buy	+1	New	+$145	﹤0.01%	570

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Ironwood Financial's VYNE Position: Q4 2021 in Review

Ironwood Financial sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 1 share.

Ironwood Financial first reported a position in VYNE in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

Ironwood Financial reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
Ironwood Financial sold 1 VYNE Therapeutics share in Q4 2021.
Ironwood Financial first reported a position in VYNE Therapeutics in Q1 2021 and held it in 3 quarters.
Ironwood Financial's VYNE Therapeutics position peaked at $0 in Q3 2021.
54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on Ironwood Financial's 13F filing for Q4 2021, filed 28 Jan 2022.